ArticleBiomedicines2023
Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Effect of high dose N-acetyl cysteine supplementation on markers of oxidative stress and insulin resistance in non-diabetic patients with metabolic dysfunction associated steatotic liver disease: a randomized controlled trial.BMC gastroenterology · 2026Trial
- Hydrogen peroxide sensing and signaling in physiology and disease: implications for therapy.Signal transduction and targeted therapy · 2026Review
- Febuxostat alleviates testicular dysfunction induced by cyclophosphamide in rats via modulation of pyroptosis and mTOR autophagy axis.Scientific reports · 2026Article
- Machine learning-based prediction model for drug target identification and MASH improvement: a comprehensive analysis of biochemical and ferroptosis/autophagy biomarkers.Journal of physiology and biochemistry · 2026Article
- Association of serum uric acid and serum uric acid/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study.BMC endocrine disorders · 2026Article
- Febuxostat Improves MASLD in Male Rats: Roles of XOR Inhibition and Associated JNK/NRF2/HO-1 Pathway Changes.International journal of molecular sciences · 2026Article
- Allopurinol Use Is Associated with Decreased Incidence of Hepatic Decompensation and Overall Mortality among Individuals with Cirrhosis: A Propensity-Matched Cohort Study.GE Portuguese journal of gastroenterology · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Children with Obesity: Sex-Stratified Analysis of Hepatic Enzyme Profiles and Serum Uric Acid.Healthcare (Basel, Switzerland) · 2025Article
- Hyperuricemia-Especially "Metabolic Hyperuricemia"-Is Independently Associated with a Higher Risk of Steatotic Liver Disease.Metabolites · 2025Article
- Uric acid as a potential marker of cardiometabolic risk in children and adolescents with metabolic dysfunction associated steatotic liver disease.Clinical and experimental hepatology · 2024Article
- From Hypothalamic Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease: Physiology Meets the Clinics via Metabolomics.Metabolites · 2024Article
- Serum uric acid and nonalcoholic fatty liver disease.Frontiers in endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) includes patients with hepatic steatosis and at least one of five cardiometabolic risk factors. Xanthine oxidase (XO) represents a treatment target for MASLD. We aimed to evaluate the effect of two xanthine oxidase inhibitors, allopurinol and febuxostat, plus lifestyle modifications compared to lifestyle modifications alone on improving steatosis. Ninety MASLD patients were assigned to one of three groups for three months. Patients with hyperuricemia were given either allopurinol 100 mg or febuxostat 40 mg daily, along with lifestyle modifications. The third control group was only given lifestyle modifications, excluding all patients with hyperuricemia due to ethical concerns. The primary outcome was to measure the change in the controlled attenuation parameter (CAP) score as an indicator of steatosis from baseline after three months. The secondary outcome was to measure the change in serum uric acid (SUA) three months from baseline. The study found that the CAP score decreased significantly in the allopurinol group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.